TARA is a Digital Behaviour Change Intervention (DBCI) for Individuals with COPD (IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology. HCD involves, among other elements, members of the target audience in evaluations at multiple stages within the design process. This feasibility study is primarily designed to assess the acceptability of the DBCI test asset to the target audience. Acceptability as defined for the purpose of this study includes usability of the system, and perceived value and desirability to the end-user audience. As such, engagement in this context is deemed to mean the degree to which the test asset provides a usable, acceptable, desirable and valuable experience to its users during a time-limited trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Patient interaction with TARA (engagement via usage data)
Data sourced from individual and amalgamated usage analytics. Data points collected from TARA Patient database / usage analytics, recording the completion with time and date stamps by the users of key sections of the TARA program. An overall score for perceived ease-of-use will be generated using the System Usability Scale (SUS) participant questionnaire
Time frame: up to 3 weeks
Assessment of usability issues
Qualitative assessment of participant's feedback on any usability issues, areas of confusion or lack of clarity whilst using TARA working prototype (version 2). Data sourced from participant's reports, emails and exit interviews.
Time frame: up to 3 weeks
Assessment of motivation and perception
Qualitative assessment of data sourced through the prototype and via discussion in the exit interview
Time frame: up to 3 weeks
Percent of individuals with COPD who achieve improvements in intention (Readiness for Change) measured by the Readiness for Change Questionnaire
Time frame: up to 3 weeks
Percent of individuals with COPD who achieve improvements in autonomous motivation measured by the Treatment Self-Regulation Questionnaire (TSRQ)
Time frame: up to 3 weeks
Percent of individuals with COPD who achieve confidence measured by the Perceived Competence Scale; PCS)
Time frame: up to 3 weeks
Percent of participants who increased adherence to once daily inhaled medication, based on Test of Adherence to Inhalers (TAI) Questionnaire
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: up to 3 weeks
Percent of participants who report increases in adherence to once daily inhaled medication, based on study-specific medication adherence question
Medication adherence question: "During the last 7 days, how many times did you forget to take your daily inhaler ?"
Time frame: up to 3 weeks
Percent of participants who report increases in adherence to once daily inhaled medication, based on prescription re-fill confirmation
Time frame: up to 3 weeks
Percent of participants who report increases in adherence to once daily inhaled medication, based on TARA daily check-in data.
Time frame: up to 3 weeks
Percent of study participants who report a reduction in COPD symptoms measured via the COPD Assessment test (CAT)
Time frame: up to 3 weeks